Innate Pharma Sa Financials

IPHA

Source SEC Filings (10-K/10-Q) Updated Apr 1, 2026 Currency USD FYE April

This page shows Innate Pharma Sa (IPHA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$50.0M

Innate Pharma Sa generated $50.0M in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

94M

Innate Pharma Sa had 94M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

IPHA Income Statement

Metric	FY25
Revenue	$50.0M
Cost of Revenue	N/A
Gross Profit	N/A
R&D Expenses	N/A
SG&A Expenses	N/A
Operating Income	N/A
Interest Expense	N/A
Income Tax	N/A
Net Income	N/A
EPS (Diluted)	N/A

Similar Companies

NeOnc Technologies Holdings Inc NTHI

$149.3M

C4 Therapeutics, Inc. CCCC

$263.5M

Elicio Therapeutics, Inc. ELTX

$196.1M

Enanta Pharmaceuticals Inc ENTA

$376.4M

Aclaris Therapeutics Inc ACRS

$501.3M

Frequently Asked Questions

What is Innate Pharma Sa's annual revenue?

Innate Pharma Sa (IPHA) reported $50.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How many shares does Innate Pharma Sa have outstanding?

Innate Pharma Sa (IPHA) had 94M shares outstanding as of fiscal year 2025.